Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$20 Mln
Revenue (TTM)
$1 Mln
Net Profit (TTM)
$0 Mln
ROE
-7.5 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
1.4
Industry P/E
44.78
EV/EBITDA
-0.5
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-108.2
Face value
--
Shares outstanding
3,393,516
CFO
$-83.75 Mln
EBITDA
$-60.27 Mln
Net Profit
$-171.09 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Predictive Oncology (POAI)
| -- | 15.3 | -49.1 | -64.3 | -63.8 | -52.1 | -64.0 |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
Predictive Oncology (POAI)
| -74.8 | -46.3 | -67.8 | 30.0 | -71.9 | -57.8 | -38.5 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Predictive Oncology (POAI)
|
6.9 | 20.2 | 0.7 | -84.3 | -11,540.4 | -- | -- | 1.4 |
| 2.3 | 4.4 | 2.7 | -3.6 | -259.4 | -9.1 | -- | 0.0 |
Predictive Oncology Inc., a knowledge and science-driven company, applies artificial intelligence (AI) to support the discovery and development of cancer therapies. It operates through two segments, Pittsburgh and Eagan. The Pittsburgh segment... provides services that include the application of AI using its proprietary biobank of 150,000+ tumor samples. This segment also creates proprietary 3D culture models used in drug development. Its Eagan segment produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. Predictive Oncology Inc. has a strategic collaboration with Every Cure to identify and prioritize drugs for repurposing. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is headquartered in Pittsburgh, Pennsylvania. Read more
CEO & Chairman
Mr. Raymond F. Vennare
CEO & Chairman
Mr. Raymond F. Vennare
Headquarters
Pittsburgh, PA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Predictive Oncology Inc (POAI) is $6.86 (NASDAQ) as of 14-Jan-2026 09:30 EDT. Predictive Oncology Inc (POAI) has given a return of -63.81% in the last 3 years.
Since, TTM earnings of Predictive Oncology Inc (POAI) is negative, P/E ratio is not available.
The P/B ratio of Predictive Oncology Inc (POAI) is 1.43 times as on 14-Jan-2026, a 52 discount to its peers’ median range of 2.95 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2024
|
-0.37
|
-22.07
|
|
2023
|
-0.96
|
1.62
|
|
2022
|
-0.05
|
0.06
|
|
2021
|
-0.16
|
0.08
|
|
2020
|
-0.03
|
0.25
|
The 52-week high and low of Predictive Oncology Inc (POAI) are Rs 39.00 and Rs 3.88 as of 06-Apr-2026.
Predictive Oncology Inc (POAI) has a market capitalisation of $ 20 Mln as on 14-Jan-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Predictive Oncology Inc (POAI), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$1.38
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.